• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1999-2019 年韩国原发性皮肤恶性肿瘤的发病率和生存率:一项全国基于人群的研究。

Incidence and survival rates of primary cutaneous malignancies in Korea, 1999-2019: A nationwide population-based study.

机构信息

Department of Dermatology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.

Department of Dermatology, Hanyang University Guri Hospital, Guri, Korea.

出版信息

J Dermatol. 2024 Apr;51(4):532-538. doi: 10.1111/1346-8138.17118. Epub 2024 Feb 17.

DOI:10.1111/1346-8138.17118
PMID:38366757
Abstract

Primary cutaneous malignancies are among the most commonly diagnosed types of cancer worldwide. We aimed to examine the incidence and 5-year survival rates of all types of primary cutaneous malignancies in the Korean population. Data from the Korean Nationwide Cancer Registry from 1999 to 2019 were analyzed. The crude incidence rates, age-standardized incidence rates, and 5-year relative survival rates of each type of skin cancer were calculated. A total of 89 965 patients were diagnosed with primary cutaneous malignancies, which was a 7-fold increase from 1999 to 2019. The age-standardized incidence rates increased 3.4-fold in basal cell carcinoma (3.7/100 000 person-years), 2.0-fold in squamous cell carcinoma (1.6/100 000 person-years), 12.0-fold in Bowen disease (1.2/100 000 person-years), and 1.8-fold in malignant melanoma (0.7/10 000 person-years) in 2019. Average annual percentage changes in age-standardized incidence rates were statistically significant in basal cell carcinoma (15.8%), Bowen disease (5.8%), squamous cell carcinoma (5.1%), malignant melanoma (1.2%), melanoma in situ (1.1%), dermatofibrosarcoma protuberans (1.2%), mycosis fungoides (0.5%), primary cutaneous CD30+ T-cell proliferations (0.5%), adnexal and skin appendage carcinoma (0.4%), extramammary Paget's disease (0.2%), and Merkel cell carcinoma (0.2%). The 5-year relative survival rates were the highest in basal cell carcinoma (103.3%), followed by dermatofibrosarcoma protuberans (99.7%) and mycosis fungoides (96.6%), and lowest in angiosarcoma (24.7%). The 5-year relative survival rates steadily increased in extramammary Paget's disease (23.6%), cutaneous B-cell lymphoma (21.3%), mycosis fungoides (20.2%), extranodal NK/T-cell lymphoma, nasal type (18.1%), and malignant melanoma (16.1%) from 1996-2000 to 2015-2019. Most primary cutaneous malignancies have increased in incidence and survival rates in the Korean population, but to varying extents depending on the type of skin cancer.

摘要

原发性皮肤恶性肿瘤是全球最常见的癌症类型之一。本研究旨在探讨韩国人群中所有原发性皮肤恶性肿瘤的发病率和 5 年生存率。对 1999 年至 2019 年韩国全国癌症登记处的数据进行了分析。计算了每种皮肤癌的粗发病率、年龄标准化发病率和 5 年相对生存率。共有 89965 例患者被诊断为原发性皮肤恶性肿瘤,与 1999 年相比增加了 7 倍。2019 年,基底细胞癌的年龄标准化发病率增加了 3.4 倍(3.7/10 万人口/年),鳞状细胞癌增加了 2.0 倍(1.6/10 万人口/年), Bowen 病增加了 12.0 倍(1.2/10 万人口/年),恶性黑色素瘤增加了 1.8 倍(0.7/10 000 人口/年)。基底细胞癌(15.8%)、 Bowen 病(5.8%)、鳞状细胞癌(5.1%)、恶性黑色素瘤(1.2%)、原位黑色素瘤(1.1%)、隆突性皮肤纤维肉瘤(1.2%)、蕈样真菌病(0.5%)、原发性皮肤 CD30+T 细胞增生(0.5%)、附属器和皮肤附件癌(0.4%)、乳腺外 Paget 病(0.2%)和 Merkel 细胞癌(0.2%)的年龄标准化发病率的年均变化率具有统计学意义。基底细胞癌的 5 年相对生存率最高(103.3%),其次是隆突性皮肤纤维肉瘤(99.7%)和蕈样真菌病(96.6%),而血管肉瘤的 5 年相对生存率最低(24.7%)。1996-2000 年至 2015-2019 年,乳腺外 Paget 病(23.6%)、皮肤 B 细胞淋巴瘤(21.3%)、蕈样真菌病(20.2%)、结外 NK/T 细胞淋巴瘤,鼻型(18.1%)和恶性黑色素瘤(16.1%)的 5 年相对生存率稳步上升。在韩国人群中,大多数原发性皮肤恶性肿瘤的发病率和生存率都有所上升,但不同类型的皮肤癌上升程度不同。

相似文献

1
Incidence and survival rates of primary cutaneous malignancies in Korea, 1999-2019: A nationwide population-based study.1999-2019 年韩国原发性皮肤恶性肿瘤的发病率和生存率:一项全国基于人群的研究。
J Dermatol. 2024 Apr;51(4):532-538. doi: 10.1111/1346-8138.17118. Epub 2024 Feb 17.
2
Epidemiology of skin cancer based on Japan's National Cancer Registry 2016-2017.基于日本 2016-2017 年国家癌症登记处的皮肤癌流行病学。
Cancer Sci. 2023 Jul;114(7):2986-2992. doi: 10.1111/cas.15823. Epub 2023 Apr 24.
3
Trends in incidence and survival of patients with vulvar cancer in an Asian country: Analysis of the Korean Central Cancer Registry 1999-2018.亚洲国家外阴癌患者发病率和生存率的趋势:韩国中央癌症登记处 1999-2018 年数据分析。
Gynecol Oncol. 2022 Feb;164(2):386-392. doi: 10.1016/j.ygyno.2021.11.017. Epub 2021 Dec 7.
4
Bowen's disease, Paget's disease, and malignant melanoma in situ.鲍温病、佩吉特病和原位恶性黑色素瘤。
South Med J. 1986 Apr;79(4):410-3. doi: 10.1097/00007611-198604000-00005.
5
Recent trend in the incidence of premalignant and malignant skin lesions in Korea between 1991 and 2006.韩国 1991 年至 2006 年期间癌前和恶性皮肤病变发病率的变化趋势。
J Korean Med Sci. 2010 Jun;25(6):924-9. doi: 10.3346/jkms.2010.25.6.924. Epub 2010 May 24.
6
Incidence of cutaneous T cell lymphoma and other rare skin cancers in a defined population.特定人群中皮肤T细胞淋巴瘤及其他罕见皮肤癌的发病率。
J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):254-6. doi: 10.1016/0190-9622(90)70208-y.
7
Skin cancer in blacks in the United States.美国黑人中的皮肤癌
Dermatol Clin. 1988 Jul;6(3):397-405.
8
Nationwide Trends in the Incidence of Melanoma and Non-melanoma Skin Cancers from 1999 to 2014 in South Korea.1999 年至 2014 年韩国全国范围内黑色素瘤和非黑色素瘤皮肤癌的发病率趋势。
Cancer Res Treat. 2018 Jul;50(3):729-737. doi: 10.4143/crt.2017.166. Epub 2017 Jul 14.
9
Skin cancer in children and young adults: 28 years' experience from the Northern Region Young Person's Malignant Disease Registry, UK.儿童和青年的皮肤癌:来自英国北部地区青少年恶性疾病登记处的28年经验。
Melanoma Res. 2003 Aug;13(4):421-6. doi: 10.1097/01.cmr.0000056259.56735.eb.
10
Trends in incidence and survival analysis in non-melanoma skin cancer from 1994 to 2012 in Girona, Spain: A population-based study.1994 年至 2012 年西班牙赫罗纳地区非黑色素瘤皮肤癌发病率和生存分析趋势:一项基于人群的研究。
Cancer Epidemiol. 2016 Dec;45:6-10. doi: 10.1016/j.canep.2016.09.001. Epub 2016 Sep 14.

引用本文的文献

1
Ethnic-Specific and UV-Independent Mutational Signatures of Basal Cell Carcinoma in Koreans.韩国人基底细胞癌的种族特异性和紫外线非依赖性突变特征
Int J Mol Sci. 2025 Jul 19;26(14):6941. doi: 10.3390/ijms26146941.